Page 52 - Read Online

Fetro. Rare Dis Orphan Drugs J 2023;2:7 https://dx.doi.org/10.20517/rdodj.2023.06 Page 15 of 16

5. European Medicines Agency. Support for development of orphan medicines. Available from: https://www.ema.europa.eu/en/
documents/report/report-workshop-support-orphan-medicines-development_en.pdf [Last accessed on 7 Apr 2023].
6. Southall NT, Natarajan M, Lau LPL, et al; IRDiRC Data Mining and Repurposing Task Force. The use or generation of biomedical
data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC
Data Mining and Repurposing Task Force. Orphanet J Rare Dis 2019;14:225. DOI PubMed PMC
7. Begley CG, Ashton M, Baell J, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci
Transl Med 2021;13:eabd5524. DOI PubMed
8. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 2014;10:654-63. DOI
PubMed PMC
9. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat
Rev Drug Discov 2006;5:689-702. DOI PubMed PMC
10. Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol 2020;72:1145-51. DOI
PubMed PMC
11. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006;2:411-22. DOI
PubMed PMC
12. Roy S, Kloner RA, Salloum FN, Jovin IS. Cardiac effects of phosphodiesterase-5 inhibitors: efficacy and safety. Cardiovasc Drugs
Ther 2021. DOI PubMed PMC
13. Pan Y, Cheng T, Wang Y, Bryant SH. Pathway analysis for drug repositioning based on public database mining. J Chem Inf Model
2014;54:407-18. DOI PubMed PMC
14. Pagliazzi A, Oranges T, Traficante G, et al. PIK3CA-related overgrowth spectrum from diagnosis to targeted therapy: a case of
CLOVES syndrome treated with Alpelisib. Front Pediatr 2021;9:732836. DOI PubMed PMC
15. Scherman D, Fetro C. Drug repositioning for rare diseases: knowledge-based success stories. Therapie 2020;75:161-7. DOI PubMed
16. Chang DY, Ma WL, Lu YS. Role of Alpelisib in the treatment of PIK3CA-mutated breast cancer: patient selection and clinical
perspectives. Ther Clin Risk Manag 2021;17:193-207. DOI PubMed PMC
17. Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med
2018;24:856-70. DOI PubMed PMC
18. Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 2018;558:540-6.
DOI PubMed PMC
19. Canaud G, López Gutiérrez J, Irvine A, et al. LBA23 EPIK-P1: retrospective chart review study of patients (pts) with PIK3CA-related
Overgrowth Spectrum (PROS) who have received alpelisib (ALP) as part of a compassionate use programme. Ann Oncol
2021;32:S1297. DOI
20. Rosenblatt M. How academia and the pharmaceutical industry can work together: the president’s lecture, annual meeting of the
American Thoracic Society, San Francisco, California. Ann Am Thorac Soc 2013;10:31-8. DOI PubMed
21. den Berg S, de Visser S, Leufkens HGM, Hollak CEM. Drug repurposing for rare diseases: a role for academia. Front Pharmacol
2021;12:746987. DOI PubMed PMC
22. Hernandez JJ, Pryszlak M, Smith L, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing
approved drugs as cancer therapeutics. Front Oncol 2017;7:273. DOI PubMed PMC
23. Fetro C, Scherman D. Drug repurposing in rare diseases: myths and reality. Therapie 2020;75:157-60. DOI PubMed
24. Bharadwaj PR, Bates KA, Porter T, et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s
and other neurodegenerative diseases. Transl Psychiatry 2013;3:e332. DOI PubMed PMC
25. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug
Discov 2011;10:712. DOI PubMed
26. WHO-EURO. Repurposing of medicines - the underrated champion of sustainable innovation: policy brief. Available from: https://
apps.who.int/iris/handle/10665/342567 [Last accessed on 7 Apr 2023].
27. Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol
2018;175:168-80. DOI PubMed PMC
28. Conour J. Why method of treatment patents for repurposed drugs are worth the investment.
https://www.jdsupra.com/legalnews/why-method-of-treatment-patents-for-92813/ [Last accessed on 7 Apr 2023].
29. Verbaanderd C, Rooman I, Huys I. Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical
research. Trials 2021;22:322. DOI PubMed PMC
30. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of
infancy. N Engl J Med 2008;358:2649-51. DOI PubMed
31. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus
conference. Pediatrics 2013;131:128-40. DOI PubMed PMC
32. U.S. Department of Health and Human Services; Food and Drug Administration. Best practices in developing proprietary names for
human prescription drug products guidance for industry. https://www.fda.gov/media/88496/download [Last accessed on 7 Apr 2023].
33. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma.
N Engl J Med 2015;372:735-46. DOI PubMed
34. Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting.